LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

详细信息    查看全文

• 作者：S. Betty Yan (1)
  Victoria L. Peek (1)
  Rose Ajamie (1)
  Sean G. Buchanan (1)
  Jeremy R. Graff (1)
  Steven A. Heidler (1)
  Yu-Hua Hui (1)
  Karen L. Huss (1)
  Bruce W. Konicek (1)
  Jason R. Manro (1)
  Chuan Shih (2)
  Julie A. Stewart (1)
  Trent R. Stewart (1)
  Stephanie L. Stout (1)
  Mark T. Uhlik (1)
  Suzane L. Um (1)
  Yong Wang (1)
  Wenjuan Wu (1)
  Lei Yan (1)
  Wei J. Yang (3)
  Boyu Zhong (2)
  Richard A. Walgren (1)
  
• 关键词：MET inhibitor ; LY2801653 ; MST1R ; MKNK ; ROS1
• 刊名：Investigational New Drugs
• 出版年：2013
• 出版时间：August 2013
• 年：2013
• 卷：31
• 期：4
• 页码：833-844
• 全文大小：704KB
• 参考文献：1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915鈥?5 CrossRef
  2. Comoglio PM, Giordano A, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Disc 7:504鈥?6 CrossRef
  3. Turke AB, Zejnullahum K, Wu YL, Song Y, Dias-Santagata D, Lifshits E et al (2010) Preexistence and clonal selection of Met amplification in EGFR mutant NSCLC. Cancer Cell 17:77鈥?8 j.ccr.2009.11.022">CrossRef
  4. Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K et al (2011) Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thoracic Oncol 7:272鈥?0 CrossRef
  5. Bean J, Brennan C, Shih JY, Riely GJ, Viale A, Wang L et al (2007) Met amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Nat鈥檒 Acad Sci USA 104:20932鈥? CrossRef
  6. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al (2007) Met amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039鈥?3 CrossRef
  7. Benvenuti S, Lazzari L, Arnesano A, Chiavi GL, Gentile A, Comoglio PM (2011) RON kinase trans-phosphorylation sustains MET oncogene addition. Cancer Res 71:1945鈥?5 CrossRef
  8. Yeh CY, Shih SM, Yeh HH, Wu TJ, Shin JW, Chang TY et al (2011) Transcriptional activation of the Axl and PDGFR-alpha by cMet through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer 11:139 CrossRef
  9. Li T, Pobanz MA, Shih C, Wu Z, Yang WJ, Zhong B (2011) Amidophenoxyindazoles useful as inhibitors of c-Met. US 8030302B2
  10. Wang W, Marimuthu A, Tsai J, Kumar A, Krupka HI, Zhang C et al (2006) Structural characterization of autoinhibited c-MET kinase produced by coexpression in bacteria with phosphatase. Proc Nat鈥檒 Acad Sci USA 103:3563鈥? CrossRef
  11. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Cryst Section D D60:2126鈥?2 CrossRef
  12. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Cryst Section D D53:240鈥?5 CrossRef
  13. Rong S, Oskarsson M, Faletto D, Tsarfaty I, Resau JH, Nakamura T et al (1993) Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ 4:563鈥?
  14. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude GF (1987) Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Nat鈥檒 Acad Sci USA 84:6379鈥?3 CrossRef
  15. Aarts LH, Roovers O, Ward AC, Touw IP (2004) Receptor activation and 2 distinct COOH-terminal motifs control G-CSF receptor distribution and internalization kinetics. Blood 103:571鈥? CrossRef
  16. Meier T, Uhlik MT, Chintharlapalli S, Dowless M, Van Horn R, Stewart J et al (2011) Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization. Mol Cancer Ther 10:2168鈥?8 CrossRef
  17. Underiner TL, Herbertz T, Miknyoczki SJ (2010) Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anti-cancer agents Med Chem 10:7鈥?7 CrossRef
  18. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude GF (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89鈥?03 CrossRef
  19. Wang MH, Kurtz AL, Chen YQ (2000) Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 21:1507鈥?2 CrossRef
  20. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG (2003) Flt3 mutations in acute myeloid leukemia cell lines. Leukemia 17:120鈥? j.leu.2402740">CrossRef
  21. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68鈥?3 CrossRef
  22. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, De Stefani A et al (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19:1547鈥?5 j.onc.1203455">CrossRef
  23. Sattler M, Hasina R, Reddy MM, Gangadhar T, Salgia R (2011) The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 3:171鈥?4 CrossRef
  24. Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E et al (2010) Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 430:425鈥?7 CrossRef
  25. Jauch R, Cho MK, Jakel S, Netter C, Schreiter K, Aicher B et al (2006) Mitogen-activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment. EMBO J 25:4020鈥?2 j.emboj.7601285">CrossRef
  26. Jauch R, J盲kel S, Netter C, Schreiter K, Aicher B, J盲ckle H et al (2005) Crystal structures of the Mnk2 kinase domain reveal an Inhibitory conformation and a zinc binding site. Structure 13:1559鈥?8 j.str.2005.07.013">CrossRef
  27. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T et al (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44:852鈥?0 CrossRef
  28. DaSilva J, Xu L, Kim HJ, Miller WT, Bar-Sagi D (2006) Regulation of sprouty stability by Mnk-1-dependent phosphorylation. Mol Cell Biol 26:1898鈥?07 CrossRef
  29. Ueda T, Sasaki M, Elia AJ, Chio LIC, Hamada K, Fukunaga R et al (2010) Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Nat鈥檒 Acad Sci USA 107:13984鈥?0 CrossRef
  30. El-Deeb IM, Yoo KH, Lee SH (2010) ROS receptor tyrosine kinase: a new potential target for anticancer drugs. Med Res Rev. doi:10.1002/med.20206:1-25
  31. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190鈥?03 j.cell.2007.11.025">CrossRef
  32. Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V et al (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6:e15640 journal.pone.0015640">CrossRef
  33. Bergethon K, Shaw AT, Ou SHI, Katayama R, Lovly CM, McDonald NT et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863鈥?0 CrossRef
  34. Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M et al (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72:2501鈥?1 CrossRef
  35. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Dis 1:78鈥?9 CrossRef
  36. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58鈥?2 CrossRef
  37. Sengupta S, Gherardi E, Sellers LA, Wood JM, Sasisekharan R, Fan TPD (2003) Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 23:69鈥?5 CrossRef
  38. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S (2011) Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 10:1763鈥?3 CrossRef
  39. Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10:575鈥?5 CrossRef
  
• 作者单位：S. Betty Yan (1)
  Victoria L. Peek (1)
  Rose Ajamie (1)
  Sean G. Buchanan (1)
  Jeremy R. Graff (1)
  Steven A. Heidler (1)
  Yu-Hua Hui (1)
  Karen L. Huss (1)
  Bruce W. Konicek (1)
  Jason R. Manro (1)
  Chuan Shih (2)
  Julie A. Stewart (1)
  Trent R. Stewart (1)
  Stephanie L. Stout (1)
  Mark T. Uhlik (1)
  Suzane L. Um (1)
  Yong Wang (1)
  Wenjuan Wu (1)
  Lei Yan (1)
  Wei J. Yang (3)
  Boyu Zhong (2)
  Richard A. Walgren (1)
  
  1. Lilly Research Laboratories, Eli Lilly and Company, DC0522, 307 E. McCarty Street, Indianapolis, IN, 46285, USA
  2. Formerly at Eli Lilly and Company, currently with Crown Biosciences Inc, Jiangsu, China
  3. Formerly at Eli Lilly and Company, currently with Johnson & Johnson, Jiangsu, China
  

文摘